223 related articles for article (PubMed ID: 34967922)
1. Oligosarcomas, IDH-mutant are distinct and aggressive.
Suwala AK; Felix M; Friedel D; Stichel D; Schrimpf D; Hinz F; Hewer E; Schweizer L; Dohmen H; Pohl U; Staszewski O; Korshunov A; Stein M; Wongsurawat T; Cheunsuacchon P; Sathornsumetee S; Koelsche C; Turner C; Le Rhun E; Mühlebner A; Schucht P; Özduman K; Ono T; Shimizu H; Prinz M; Acker T; Herold-Mende C; Kessler T; Wick W; Capper D; Wesseling P; Sahm F; von Deimling A; Hartmann C; Reuss DE
Acta Neuropathol; 2022 Feb; 143(2):263-281. PubMed ID: 34967922
[TBL] [Abstract][Full Text] [Related]
2. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
3. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Ono T; Reinhardt A; Takahashi M; Nanjo H; Kamataki A; von Deimling A; Shimizu H
Acta Neurochir (Wien); 2020 Dec; 162(12):3019-3024. PubMed ID: 32785787
[TBL] [Abstract][Full Text] [Related]
4. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
5. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
[TBL] [Abstract][Full Text] [Related]
6. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
7. Recurrent oligodendroglioma with changed 1p/19q status.
Barresi V; Mafficini A; Calicchia M; Piredda ML; Musumeci A; Ghimenton C; Scarpa A
Neuropathology; 2022 Apr; 42(2):160-166. PubMed ID: 35144313
[TBL] [Abstract][Full Text] [Related]
8. Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Vajtai I; Vassella E; Hewer E; Kappeler A; Reinert MM
Pathol Res Pract; 2012 Dec; 208(12):750-5. PubMed ID: 23102810
[TBL] [Abstract][Full Text] [Related]
9. Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses.
Tanaka S; Hitotsumatsu T; Sugita Y; Ishido K; Ito O; Hatae R; Akagi Y; Yoshimoto K; Iihara K
Pathol Int; 2018 Oct; 68(10):567-573. PubMed ID: 30246385
[TBL] [Abstract][Full Text] [Related]
10. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
[TBL] [Abstract][Full Text] [Related]
11. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
12. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
13. Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Mur P; Mollejo M; Ruano Y; de Lope ÁR; Fiaño C; García JF; Castresana JS; Hernández-Laín A; Rey JA; Meléndez B
Acta Neuropathol; 2013 Aug; 126(2):277-89. PubMed ID: 23689617
[TBL] [Abstract][Full Text] [Related]
14. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
[TBL] [Abstract][Full Text] [Related]
15. Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
Yasuda T; Nitta M; Komori T; Kobayashi T; Masui K; Maruyama T; Sawada T; Muragaki Y; Kawamata T
Neuropathology; 2018 Feb; 38(1):41-46. PubMed ID: 28812310
[TBL] [Abstract][Full Text] [Related]
16. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
[TBL] [Abstract][Full Text] [Related]
17. Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas.
Wongsurawat T; Jenjaroenpun P; Anekwiang P; Arigul T; Thongrattana W; Jamshidi-Parsian A; Boysen G; Suriyaphol P; Suktitipat B; Srirabheebhat P; Cheunsuchon P; Tanboon J; Nookaew I; Sathornsumetee S
Brain Pathol; 2024 Jan; 34(1):e13203. PubMed ID: 37574201
[TBL] [Abstract][Full Text] [Related]
18. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
19. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
20. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]